Patent Application
20240241292
This application claims the benefit of Taiwan application Serial No. 112100906, filed Jan. 9, 2023, and Taiwan application Serial No. 112144583, filed Nov. 17, 2023, the subject matters of which are incorporated herein by references.
The disclosure relates to a composition for contact lens and a contact lens made from the composition.
Soft contact lenses are popular with people due to their cosmetic, comfort and convenience properties. When evaluating the quality of soft contact lenses, oxygen permeability (Dk) and mechanical property are very important factors. The oxygen permeability may express the ability of the lens to let oxygen pass through the lens. Corneal hypoxia, corneal injury, eye infection, wearing comfort and other problems may be improved by increasing the oxygen permeability. The mechanical property may express whether the contact lens is strong enough to withstand the user's operations such as wearing, taking off, and cleaning without breaking. Elongation is one of the index for evaluating mechanical property. Low elongation may cause the contact lens to break easily, affecting the durability and lifespan of the contact lens. However, conventional soft contact lenses are difficult to balance the oxygen permeability and elongation. The increase of oxygen permeability may reduce the elongation to the point of making contact lenses prone to breakage, the increase of elongation may reduce the oxygen permeability and thus affect the wearing comfort.
Therefore, how to get balance between the oxygen permeability and elongation of soft contact lens in the appropriate range is still an urgent problem to be solved.
According to an embodiment, a composition for contact lens is provided. The composition for a contact lens includes a siloxane mixture, a tris(trimethylsiloxy)silypropyl methacrylate, and a hydrophilic monomer. The siloxane mixture includes a first siloxane monomer and a second siloxane monomer. The first siloxane monomer has an acryloyl group. The second siloxane monomer has two acryloyl groups. A weight ratio of the siloxane mixture to the tris(trimethylsiloxy)silypropyl methacrylate is between about 27.5:1 and about 0.29:1.
According to an embodiment, a contact lens is provided. The contact lens has an oxygen permeability (Dk) of greater than 80 and an elongation of greater than 270%.
The above and other embodiments of the disclosure will become better understood with regard to the following detailed description of the non-limiting embodiment(s).
For facilitating understanding the above embodiments and other purposes, characteristics and advantages of the present disclosure, preferred embodiments are disclosed in detail as the following.
According to an embodiment of the present disclosure, a composition for contact lens is provided. The composition includes a siloxane mixture, a tris(trimethylsiloxy)silypropyl methacrylate (TRIS), and a hydrophilic monomer.
The siloxane mixture includes a first siloxane monomer and a second siloxane monomer. The first siloxane monomer is different from the second siloxane monomer.
The first siloxane monomer has an acryloyl group. For example, the acryloyl group can be represented as
A number-average molecular weight of the first siloxane monomer is about 500˜10000. In an embodiment, the first siloxane monomer is represented by the following formula (1).
In the formula (1), R1, R2 and R3 are each independently C1-C4 alkyl group; R4 is C1-C6 alkyl group; n is 4˜80; X is represented by the following formula (1-1), the following formula (1-2) or the following formula (1-3). In the formula (1-1), formula (1-2) and formula (1-3), the sign * on the left of each formula represents a chemical bond with Si in the formula (1), and the sign * on the right of each formula represents a chemical bond with C in the formula (1).
In the formula (1-1), R5 is a residue obtained by removing NCO group from an aliphatic or aromatic diisocyanate; m is 3˜40. In the formula (1-2), R8 is C1-C4 alkylene group; R9 is —OR10O— or —NH—; R10 and R11 are each independently C1-C4 alkylene group; p is 1˜2.
In an embodiment, the first siloxane monomer is represented by the following formula (1A).
In the formula (1A), h is an integer from 4 to 80; i is an integer from 3 to 40. A number-average molecular weight of the first siloxane monomer is about 1000˜10000.
In an embodiment, the first siloxane monomer is represented by the following formula (1B) or the following formula (1C).
In the formula (1B), rr is an integer from 4 to 80. In the formula (1C), ss is an integer from 4 to 80.
In an embodiment, the first siloxane monomer is monomethacryloxypropyl propyl functional polydimethyl methoxy alkane. In an embodiment, the first siloxane monomer is MCR-M07 or MCR-M11 obtained from Gelest Inc., Morrisville, PA, USA.
The second siloxane monomer has two acryloyl groups. For example, the acryloyl group can be represented as
A number-average molecular weight of the second siloxane monomer is about 1000˜25000. The second siloxane monomer is represented by the following formula (2) or the following formula (3).
In the formula (2), R31 and R32 are each independently C1-C4 alkyl group; q is 4˜120; Y is represented by the following formula (2-1) or the following formula (2-2); Z is represented by the following formula (2-3) or the following formula (2-4). In the formula (2-1) and formula (2-2), the sign * on the left of each formula represents a chemical bond with C in the formula (2), and the sign * on the right of each formula represents a chemical bond with Si in the formula (2). In the formula (2-3) and formula (2-4), the sign * on the left of each formula represents a chemical bond with Si in the formula (2), and the sign * on the right of each formula represents a chemical bond with C in the formula (2).
In the formula (2-3), R33 is C1-C4 alkyl group. In the formula (2-1) and formula (2-3), R34 is C1-C3 alkylene group; R35 and R37 are each independently C1-C3 alkylene group; R36 is a residue obtained by removing NCO group from an aliphatic or aromatic diisocyanate; f is 0˜1; g is 1˜40.
In the formula (3), T is a polymerizable, free radical polymerizably active, unsaturated group bonded through a divalent hydrocarbon group; R38 and R39 are each independently C1-C20 hydrocarbon group or C1-C20 halogenated hydrocarbon group; R40, R41, R42 and R43 are each independently selected from a group consisting of C1-C20 monovalent hydrocarbon group, C1-C20 halogenated monovalent hydrocarbon group and a hydrophilic sidechain; q1 is 1˜1000; q2 is 1˜1000. The hydrophilic sidechain can be represented by the following formula (3-1) or the following formula (3-2).
In the formula (3-1), R44 is a C1-C10 divalent hydrocarbon group, R45 is hydrogen or methyl, R46 is selected from a group consisting of hydrogen, C1-C10 monovalent hydrocarbon group, and the group represented by the following formula (3-3), q3 is an integer greater than or equal to 1, and the sign * represents a chemical bond with Si in the formula (3). In the formula (3-2), R47 is C1-C10 divalent hydrocarbon group, R48 is hydrogen or methyl, R49 is selected from a group consisting of hydrogen, C1-C10 monovalent hydrocarbon group, and the group represented by the following formula (3-4), q4 is an integer greater than or equal to 1, and the sign * represents a chemical bond with Si in the formula (3).
In the formula (3-3), R50 is selected from a group consisting of C1-C10 monovalent hydrocarbon, hydrogen and OH, and the sign * represents a chemical bond with O in the formula (3-1). In the formula (3-4), R51 is selected from a group consisting of C1-C10 monovalent hydrocarbon, hydrogen and OH, and the sign * represents a chemical bond with N in the formula (3-2).
In an embodiment, the second siloxane monomer is represented by the formula (2), Y in the formula (2) is represented by the formula (2-1), and Z in the formula (2) is represented by the formula (2-3); R31 and R32 are each independently C1-C4 alkyl group; R33 is C1-C4 alkyl group; R34 is C1-C3 alkylene group; R35 and R37 are each independently C1-C3 alkylene group; R36 is a residue obtained by removing NCO group from an aliphatic or aromatic diisocyanate; q is an integer from 4 to 80; f is an integer from 0 to 1; g is an integer from 1 to 20. In this embodiment, a number-average molecular weight of the second siloxane monomer is about 1000˜10000.
In an embodiment, the second siloxane monomer is represented by the formula (3), T is a group represented by the following formula (3-5) or the following formula (3-6), q5 in the formula (3-5) is an integer from 1 to 10, and q6 in the formula (3-6) is an integer from 1 to 10; R38 and R39 are each independently C1-C4 hydrocarbon; R40, R41, R42 and R43 are each independently selected from a group consisting of C1-C20 monovalent hydrocarbon group, C1-C20 halogenated monovalent hydrocarbon group and a hydrophilic sidechain, and at least one of R40, R41, R42 and R43 is a hydrophilic sidechain represented by the above formula (3-1) or the above formula (3-2); q1 is an integer from 1 to 300; q2 is an integer from 1 to 300. In the present embodiment, R44 in the formula (3-1) is C1-C6 divalent hydrocarbon group, R45 in the formula (3-1) is hydrogen or methyl, R46 in the formula (3-1) is the group represented by the above formula (3-3) and R50 is selected from a group consisting of C1-C4 monovalent hydrocarbon, hydrogen and OH, and q3 in the formula (3-1) is an integer from 1 to 20. In the present embodiment, R47 in the formula (3-2) is C1-C6 divalent hydrocarbon group, R48 in the formula (3-2) is hydrogen or methyl, R49 in the formula (3-2) is the group represented by the above formula (3-4) and R51 is selected from a group consisting of C1-C4 monovalent hydrocarbon, hydrogen and OH, and q4 in the formula (3-2) is an integer from 1 to 20.
In an embodiment, the second siloxane monomer is represented by the formula (3), T is a group represented by the above formula (3-5) or the above formula (3-6), q5 in the formula (3-5) is an integer from 1 to 10, and q6 in the formula (3-6) is an integer from 1 to 10; R38 and R39 are each independently C1-C4 hydrocarbon; only one of R40, R41, R42 and R43 is a hydrophilic sidechain represented by the above formula (3-1) or the above formula (3-2), and the others of R40, R41, R42 and R43 are each independently selected from a group consisting of C1-C20 monovalent hydrocarbon group and C1-C20 halogenated monovalent hydrocarbon group; q1 is an integer from 1 to 300; q2 is an integer from 1 to 300. In the present embodiment, R44 in the formula (3-1) is C1-C6 divalent hydrocarbon group, R45 in the formula (3-1) is hydrogen or methyl, R46 in the formula (3-1) is the group represented by the above formula (3-3) and R50 is selected from a group consisting of C1-C4 monovalent hydrocarbon, hydrogen and OH, and q3 in the formula (3-1) is an integer from 1 to 20. In the present embodiment, R47 in the formula (3-2) is C1-C6 divalent hydrocarbon group, R48 in the formula (3-2) is hydrogen or methyl, R49 in the formula (3-2) is the group represented by the above formula (3-4) and R51 is selected from a group consisting of C1-C4 monovalent hydrocarbon, hydrogen and OH, and q4 in the formula (3-2) is an integer from 1 to 20.
In an embodiment, the second siloxane monomer is represented by the formula (3), T is a group represented by the above formula (3-5) or the above formula (3-6), q5 in the formula (3-5) is an integer from 1 to 10, and q6 in the formula (3-6) is an integer from 1 to 10; R38 and R39 are each independently C1-C4 hydrocarbon; R40, R41, R42 and R43 are each independently selected from a group consisting of C1-C20 monovalent hydrocarbon group, C1-C20 halogenated monovalent hydrocarbon group and a hydrophilic sidechain, and at least one of R40, R41, R42 and R43 is a hydrophilic sidechain represented by the above formula (3-1) or the above formula (3-2); q1 is an integer from 1 to 200; q2 is an integer from 1 to 200. In the present embodiment, R44 in the formula (3-1) is C1-C6 divalent hydrocarbon group, R45 in the formula (3-1) is hydrogen or methyl, R46 in the formula (3-1) is the group represented by the above formula (3-3) and R50 is selected from a group consisting of CH3, H and OH, and q3 in the formula (3-1) is an integer from 1 to 20. In the present embodiment, R47 in the formula (3-2) is C1-C6 divalent hydrocarbon group, R48 in the formula (3-2) is hydrogen or methyl, R49 in the formula (3-2) is the group represented by the above formula (3-4) and R51 is selected from a group consisting of CH3, H and OH, and q4 in the formula (3-2) is an integer from 1 to 20.
In an embodiment, the second siloxane monomer is represented by the formula (3), T is a group represented by the above formula (3-5) or the above formula (3-6), q5 in the formula (3-5) is an integer from 1 to 10, and q6 in the formula (3-6) is an integer from 1 to 10; R38 and R39 are each independently C1-C4 hydrocarbon; only one of R40, R41, R42 and R43 is a hydrophilic sidechain represented by the above formula (3-1) or the above formula (3-2), and the others of R40, R41, R42 and R43 are each independently selected from a group consisting of C1-C20 monovalent hydrocarbon group and C1-C20 halogenated monovalent hydrocarbon group; q1 is an integer from 1 to 200; q2 is an integer from 1 to 200. In the present embodiment, R44 in the formula (3-1) is C1-C6 divalent hydrocarbon group, R45 in the formula (3-1) is hydrogen or methyl, R46 in the formula (3-1) is the group represented by the above formula (3-3) and R50 is selected from a group consisting of CH3, H and OH, and q3 in the formula (3-1) is an integer from 1 to 20. In the present embodiment, R47 in the formula (3-2) is C1-C6 divalent hydrocarbon group, R48 in the formula (3-2) is hydrogen or methyl, R49 in the formula (3-2) is the group represented by the above formula (3-4) and R51 is selected from a group consisting of CH3, H and OH, and q4 in the formula (3-2) is an integer from 1 to 20.
In an embodiment, the second siloxane monomer is represented by the following formula (2A).
In the formula (2A), qq is an integer from 4 to 80; aa is an integer from 3 to 40. In this embodiment, a number-average molecular weight of the second siloxane monomer is about 1000˜10000.
In an embodiment, the second siloxane monomer is represented by the following formula (2B).
In the formula (2B), tt is an integer from 4 to 80; bb is an integer from 1 to 10. In this embodiment, a number-average molecular weight of the second siloxane monomer is about 1000˜10000.
In an embodiment, the second siloxane monomer is represented by the following formula (2C).
In the formula (2C), kk is an integer from 80 to 160; cc is an integer from 5 to 40. In this embodiment, a number-average molecular weight of the second siloxane monomer is about 1000˜20000.
In an embodiment, the second siloxane monomer is represented by the following formula (2D).
In the formula (2D), ff is an integer from 4 to 80. In this embodiment, a number-average molecular weight of the second siloxane monomer is about 1000˜10000.
In an embodiment, the second siloxane monomer is represented by the following formula (3A).
In the formula (3A), q7 is an integer from 1 to 150, q8 is an integer from 1 to 150, and q9 is an integer from 1 to 15. In this embodiment, a number-average molecular weight of the second siloxane monomer is about 1000˜20000.
In an embodiment, the second siloxane monomer is represented by the following formula (3B).
In the formula (3B), q10 is an integer from 1 to 150, q11 is an integer from 1 to 150, and q12 is an integer from 1 to 15. In this embodiment, a number-average molecular weight of the second siloxane monomer is about 1000˜20000.
In an embodiment, the second siloxane monomer is difunctional acrylate-containing siloxane monomer methacryloxypropyl propyl terminated polydimethyl siloxanes. In an embodiment, the second siloxane monomer is DMS-R18, DMS-R22 or DMS-R31 obtained from Gelest Inc., Morrisville, PA, USA.
In an embodiment, the first siloxane monomer is in a range of 50 wt % to 91 wt %, and the second siloxane monomer is in a range of 9 wt % to 50 wt % based on the total weight of the siloxane mixture. In an embodiment, the first siloxane monomer is in a range of 60 wt % to 91 wt %, and the second siloxane monomer is in a range of 9 wt % to 40 wt % based on the total weight of the siloxane mixture. In an embodiment, the first siloxane monomer is in a range of 70 wt % to 91 wt %, and the second siloxane monomer is in a range of 9 wt % to 30 wt % based on the total weight of the siloxane mixture. In other embodiments, the siloxane mixture includes two or more different siloxane monomers.
The siloxane mixture is in a range of 10 wt % to 55 wt % based on the total weight of the composition for contact lens. Preferably, the siloxane mixture is in a range of 14 wt % to 45 wt % based on the total weight of the composition for contact lens.
<Tris(trimethylsiloxy)silypropyl methacrylate (TRIS)>
The tris(trimethylsiloxy)silypropyl methacrylate can be represented by the following formula (4).
The tris(trimethylsiloxy)silypropyl methacrylate is in a range of 2 wt % to 34 wt % based on the total weight of the composition for contact lens. Preferably, the tris(trimethylsiloxy)silypropyl methacrylate is in a range of 4 wt % to 34 wt % based on the total weight of the composition for contact lens. In the case that the tris(trimethylsiloxy)silypropyl methacrylate is less than 2 wt % based on the total weight of the composition, the mechanical strength of the contact lens made from this composition is poor and the elongation thereof is too low. In the case that the tris(trimethylsiloxy)silypropyl methacrylate is more than 34 wt % based on the total weight of the composition, the mechanical strength of the contact lens made from this composition is decreased.
In an embodiment, in the composition for contact lens, a weight ratio of the siloxane mixture to the tris(trimethylsiloxy)silypropyl methacrylate is between about 27.5:1 and about 0.29:1. In an embodiment, in the composition for contact lens, a weight ratio of the siloxane mixture to the tris(trimethylsiloxy)silypropyl methacrylate is between about 9:1 and about 3:7. For example, in the composition for contact lens, a weight ratio of the siloxane mixture to the tris(trimethylsiloxy)silypropyl methacrylate may be about 9:1, about 3:2, or about 3:7.
The hydrophilic monomer may be one or more materials selected from a group consisting of 2-hydroxyethyl methacrylate (HEMA), methyl methacrylate (MMA), methacrylic acid (MAA), N-vinyl pyrrolidone (NVP), N,N-dimethyl-acrylamide (DMA), 4-acryloylmorpholine (AcMO), 2-hydroxyethyl acrylamide (HEAA), glyceryl methacrylate (GMA), glycerol mono-methacrylate (GMMA), acrylic acid (AA), N,N-di(methyl methacryl-amide) (DMA), N-vinyl-N-methyl acetamide, glycine vinyl carbonate, hexafluoroisopropyl methacrylate (HFMA), 2-methacryloyloxyethyl phosphorylcholine, and 2-hydroxy-butyl methacrylate. In an embodiment, the hydrophilic monomer is one or more materials selected from a group consisting of 2-hydroxyethyl methacrylate (HEMA), N-vinyl pyrrolidone (NVP) and hexafluoroisopropyl methacrylate (HFMA). In an embodiment, the hydrophilic monomer includes 2-hydroxyethyl methacrylate (HEMA) and N-vinyl pyrrolidone (NVP). In an embodiment, the hydrophilic monomer includes 2-hydroxyethyl methacrylate (HEMA), N-vinyl pyrrolidone (NVP) and 4-acryloylmorpholine (AcMO). In an embodiment, the hydrophilic monomer includes 2-hydroxyethyl methacrylate (HEMA), N-vinyl pyrrolidone (NVP) and hexafluoroisopropyl methacrylate (HFMA). In an embodiment, the hydrophilic monomer includes 2-hydroxyethyl methacrylate (HEMA), N-vinyl pyrrolidone (NVP) and N,N-di(methyl meth acryl-amide) (DMA). In an embodiment, the hydrophilic monomer includes 2-hydroxyethyl methacrylate (HEMA), methacrylic acid (MAA) and methyl methacrylate (MMA).
The hydrophilic monomer is in a range of 45 wt % to 54 wt % based on the total weight of the composition for contact lens. Preferably, the hydrophilic monomer is in a range of 49 wt % to 51 wt % based on the total weight of the composition for contact lens.
In an embodiment, the composition for contact lens further includes an ultraviolet absorbing agent, a thermal initiator and/or blue light absorbing agent.
The ultraviolet absorbing agent may be one or more materials selected from a group consisting of 2-[3-(2H-benzotriazol-2-yl)-4-hydroxyphenyl]ethyl-2-methacrylate, 2-(4-benzyl-3-hydroxyphenoxy)ethyl acrylate, and N-(4-hydroxy-3(5-methoxy-2H-benzo[d][1,2,3]triazol-2-yl) phenyl)methacrylamide. In an embodiment, the ultraviolet absorbing agent is 2-[3-(2H-benzotriazol-2-yl)-4-hydroxyphenyl]ethyl-2-methacrylate.
The ultraviolet absorbing agent is in a range of 0.5 wt % to 2.5 wt % based on the total weight of the composition for contact lens.
The thermal initiator may be one or more materials selected from a group consisting of azobisisobutyronitrile, 2,2′-Azo-bis-(2-methylbutyronitrile), and azobisisoheptanenitrile. In an embodiment, the thermal initiator is azobisisobutyronitrile.
The thermal initiator is in a range of 0.45 wt % to 0.75 wt % based on the total weight of the composition for contact lens.
The blue light absorbing agent may be one or more materials selected from a group consisting of Reactive Yellow 15, Reactive Yellow 15 with modification, Reactive Yellow 86, (E)-4-Methacryloyloxyazobenzene (Y7), 2-(4-acetyl-3-amino-2,6-dimethoxyphenoxy)ethyl methacrylate, 2-(4-amino-3-propionylphenoxy)ethyl methacrylate, 2-((1-amino-8-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)ethyl methacrylate, and 2-(2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)acetoxy)ethyl methacrylate.
The Reactive Yellow 15 is represented by the following formula (5-1).
The Reactive Yellow 15 with modification is represented by the following formula (5-2).
The Reactive Yellow 86 is represented by the following formula (5-3).
The (E)-4-Methacryloyloxyazobenzene is represented by the following formula (5-4).
The 2-(4-acetyl-3-amino-2,6-dimethoxyphenoxy)ethyl methacrylate is represented by the following formula (5-5).
The 2-(4-amino-3-propionylphenoxy)ethyl methacrylate is represented by the following formula (5-6).
The 2-((1-amino-8-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)ethyl methacrylate is represented by the following formula (5-7).
The 2-(2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)acetoxy)ethyl methacrylate is represented by the following formula (5-8).
In an embodiment, the composition for contact lens further includes other additives as required. The additives include, but are not limited to, dyes.
The above components may be mixed in specific proportions to form a composition for contact lens. For example, the composition for contact lens may be a clear solution or a colored solution.
According to an embodiment, a contact lens is provided. The composition for contact lens provided by the present disclosure may be put into a contact lens mold, and each component in the composition may be reacted by heating or exposing to light to form a contact lens. The heating temperature may be between about 30° C. and about 150° C., and reaction time may be between about 1 hour and 12 hours. In an embodiment, the heating process may be performed at 30˜70° C. for 0˜2 hours, 70˜100° C. for 2˜4 hours and 100˜150° C. for 4˜12 hours.
In an embodiment, the method for forming a contact lens further includes a hydration process. The hydration process may include soaking the contact lens in alcohol and pure water, and then put the contact lens in a buffer solution to be equilibria.
The present disclosure will be explained in further detail with reference to the examples. However, the present disclosure is not limited to these examples.
The contact lens of the present disclosure has high oxygen permeability and high elongation. In an embodiment, the contact lens has an oxygen permeability of greater than 80 barrer and an elongation of greater than 270%. In an embodiment, the contact lens has an oxygen permeability of about 80˜108 barrer and an elongation of about 270%˜470%. For example, the contact lens may be a silicone hydrogel contact lens.
A composition for contact lens is formed by mixing the components according to the content (wt %) shown in the following Table 1. The composition for contact lens is put into a contact lens mold, and then a heating process is performed to the composition to form a contact lens. In the Table 1, the siloxane mixture includes the first siloxane monomer represented by the following formula (1A) and the second siloxane monomer represented by the formula (2A) or formula (2B) or formula (3A) or formula (3B); the ultraviolet absorbing agent is 2-[3-(2H-benzotriazol-2-yl)-4-hydroxyphenyl]ethyl-2-methacrylate; the thermal initiator is azobisisobutyronitrile.
The oxygen permeability and elongation of the contact lenses of Example 1, Example 2, Example 3 and Comparative Example 1 are evaluated. The oxygen permeability and elongation can be measured using conventional methods well known in the art to which the present disclosure pertains. The elongation shown below is determined using a tensile tester based on American Society for Testing and Materials (ASTM) standard D1708-18. The oxygen permeability shown below is determined using an O2 Permeometer based on the method for testing oxygen permeability according to ISO 18369-4. The unit of the oxygen permeability is barrer [10−11 (cm2/sec)(ml O2/ml·mmHg].
As shown in Table 2, each of the contact lenses of Examples 1˜3 of the present disclosure has an oxygen permeability of greater than 80 barrer and an elongation of greater than 270%. As compared with the contact lens of the comparative example, which has a low elongation and has the problem of being easily broken, the elongation of the contact lenses of the present disclosure is higher, that is, the contact lenses of the present disclosure are less likely to break when they are stretched by external force. Moreover, the contact lenses of the present disclosure still maintain high oxygen permeability, and thus they are comfortable to wear. Therefore, the composition for contact lens of the present disclosure shows high oxygen permeability and excellent mechanical property (high elongation), and has the advantages of being durable, not easily broken, and comfortable to wear.
While the disclosure has been described by way of example and in terms of the exemplary embodiment(s), it is to be understood that the disclosure is not limited thereto. On the contrary, it is intended to cover various modifications and similar arrangements and procedures, and the scope of the appended claims therefore should be accorded the broadest interpretation so as to encompass all such modifications and similar arrangements and procedures.
| Number | Date | Country | Kind |
|---|---|---|---|
| 112100906 | Jan 2023 | TW | national |
| 112144583 | Nov 2023 | TW | national |
